10.01.08
Research recently published in Molecular Vision demonstrates that the natural dietary supplement Mirtogenol—a combination of Mirtoselect standardized bilberry extract, and Pycnogenol French maritime pine bark extract—may lower high intraocular pressure (IOP), significantly reducing the likelihood of developing glaucoma.
While several circumstances are believed to be involved in the development of glaucoma, an elevated IOP represents a great variable risk factor.
The study, conducted at the University of Chieti-Pescara in San Valentino, Italy, divided 38 individuals into two groups. The first group consisted of 20 subjects who were given Mirtogenol, once in the morning and once in the evening, for 6 months. Each Mirtogenol tablet contained 40 mg of Pycnogenol French maritime pine bark extract and 80 mg of Mirtoselect standardized bilberry extract. The control group, consisting of 18 participants, were followed without treatment. IOP was measured with the standard Goldmann applanation tonometer at the same time every morning. Prior to testing, subjects had complete eye exams, ocular hypertension and no signs of glaucoma.
At the end of the testing, Mirtogenol lowered IOP in 19 of 20 patients versus one of the 18 patients in the control group. Throughout the study there was a total decrease of IOP from 25.2 mmHg to 22.0 mmHg in the Mirtogenol group (-13%) compared to the 24.6 mmHG to 24.5 mmHG in the control group (-0.4%).
For further information: 312-546-3508 or 39-02-202391.
While several circumstances are believed to be involved in the development of glaucoma, an elevated IOP represents a great variable risk factor.
The study, conducted at the University of Chieti-Pescara in San Valentino, Italy, divided 38 individuals into two groups. The first group consisted of 20 subjects who were given Mirtogenol, once in the morning and once in the evening, for 6 months. Each Mirtogenol tablet contained 40 mg of Pycnogenol French maritime pine bark extract and 80 mg of Mirtoselect standardized bilberry extract. The control group, consisting of 18 participants, were followed without treatment. IOP was measured with the standard Goldmann applanation tonometer at the same time every morning. Prior to testing, subjects had complete eye exams, ocular hypertension and no signs of glaucoma.
At the end of the testing, Mirtogenol lowered IOP in 19 of 20 patients versus one of the 18 patients in the control group. Throughout the study there was a total decrease of IOP from 25.2 mmHg to 22.0 mmHg in the Mirtogenol group (-13%) compared to the 24.6 mmHG to 24.5 mmHG in the control group (-0.4%).
For further information: 312-546-3508 or 39-02-202391.
